Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations

Jocelyn D Jones,1 Sylvia H Jackson,1 Charlie Colquitt21College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Jacksonville, FL, USA; 2College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tampa, FL, USAAbstract: Hypertension is a common disease th...

Full description

Bibliographic Details
Main Authors: Jones JD, Jackson SH, Colquitt C
Format: Article
Language:English
Published: Dove Medical Press 2013-08-01
Series:Research Reports in Clinical Cardiology
Online Access:http://www.dovepress.com/azilsartan-alone-and-in-combination-for-the-treatment-of-hypertension--a13911
_version_ 1818692417321172992
author Jones JD
Jackson SH
Colquitt C
author_facet Jones JD
Jackson SH
Colquitt C
author_sort Jones JD
collection DOAJ
description Jocelyn D Jones,1 Sylvia H Jackson,1 Charlie Colquitt21College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Jacksonville, FL, USA; 2College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tampa, FL, USAAbstract: Hypertension is a common disease that leads to significant cardiovascular morbidity and mortality. Adequate blood pressure control is essential in preventing end organ complications. One of the most popular antihypertensive strategies for the treatment of elevated blood pressure is to attenuate the actions of the renin-angiotensin-aldosterone system. The agents include the angiotensin converting enzyme inhibitors, angiotensin II receptor blockers (ARBs), direct renin inhibitors, and aldosterone antagonists. The ARBs inhibit the action of angiotensin II by binding to the angiotensin II type 1 receptor. The inhibition of angiotensin II results in a dose dependent decrease in peripheral resistance, reduction in vascular smooth muscle contraction, and reduced synthesis of aldosterone in the kidneys. Azilsartan medoxomil is a highly selective ARB. It was approved by the US Food and Drug Administration in February 2011 for the treatment of hypertension in adults. It is the eighth ARB to be added to the market. This article will discuss the pharmacologic and clinical characteristics of azilsartan medoxomil to help differentiate it from other ARBs that are used for the management of hypertension.Keywords: hypertension, azilsartan medoxomil, angiotensin II receptor blocker, ARB
first_indexed 2024-12-17T12:57:27Z
format Article
id doaj.art-1661d2548b9a4ce692ae924c260c26dc
institution Directory Open Access Journal
issn 1179-8475
language English
last_indexed 2024-12-17T12:57:27Z
publishDate 2013-08-01
publisher Dove Medical Press
record_format Article
series Research Reports in Clinical Cardiology
spelling doaj.art-1661d2548b9a4ce692ae924c260c26dc2022-12-21T21:47:27ZengDove Medical PressResearch Reports in Clinical Cardiology1179-84752013-08-012013default125133Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerationsJones JDJackson SHColquitt CJocelyn D Jones,1 Sylvia H Jackson,1 Charlie Colquitt21College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Jacksonville, FL, USA; 2College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tampa, FL, USAAbstract: Hypertension is a common disease that leads to significant cardiovascular morbidity and mortality. Adequate blood pressure control is essential in preventing end organ complications. One of the most popular antihypertensive strategies for the treatment of elevated blood pressure is to attenuate the actions of the renin-angiotensin-aldosterone system. The agents include the angiotensin converting enzyme inhibitors, angiotensin II receptor blockers (ARBs), direct renin inhibitors, and aldosterone antagonists. The ARBs inhibit the action of angiotensin II by binding to the angiotensin II type 1 receptor. The inhibition of angiotensin II results in a dose dependent decrease in peripheral resistance, reduction in vascular smooth muscle contraction, and reduced synthesis of aldosterone in the kidneys. Azilsartan medoxomil is a highly selective ARB. It was approved by the US Food and Drug Administration in February 2011 for the treatment of hypertension in adults. It is the eighth ARB to be added to the market. This article will discuss the pharmacologic and clinical characteristics of azilsartan medoxomil to help differentiate it from other ARBs that are used for the management of hypertension.Keywords: hypertension, azilsartan medoxomil, angiotensin II receptor blocker, ARBhttp://www.dovepress.com/azilsartan-alone-and-in-combination-for-the-treatment-of-hypertension--a13911
spellingShingle Jones JD
Jackson SH
Colquitt C
Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations
Research Reports in Clinical Cardiology
title Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations
title_full Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations
title_fullStr Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations
title_full_unstemmed Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations
title_short Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations
title_sort azilsartan alone and in combination for the treatment of hypertension ndash clinical utility and patient considerations
url http://www.dovepress.com/azilsartan-alone-and-in-combination-for-the-treatment-of-hypertension--a13911
work_keys_str_mv AT jonesjd azilsartanaloneandincombinationforthetreatmentofhypertensionndashclinicalutilityandpatientconsiderations
AT jacksonsh azilsartanaloneandincombinationforthetreatmentofhypertensionndashclinicalutilityandpatientconsiderations
AT colquittc azilsartanaloneandincombinationforthetreatmentofhypertensionndashclinicalutilityandpatientconsiderations